ID
84
Cancer Name
Brain Oligodendroglioma – Adult Form
Main Grouping
Nervous System
Organ System
Brain
Cell Origin
Oligodendrocytes
Pathways Affected
Oligodendroglioma involves a uniquely defined pathway landscape anchored by the IDH mutation/D-2HG oncometabolite creating the G-CIMP epigenetic reprogramming, the 1p/19q codeletion/CIC/FUBP1 tumor suppressor loss pathway, TERT promoter-driven telomere maintenance, and downstream PI3K/AKT/mTOR and MAPK/ERK proliferative signaling.
The IDH mutation/D-2HG/TCA cycle pathway is the single most fundamental and defining oncogenic event in oligodendroglioma: IDH1 R132H or IDH2 R172 gain-of-function mutations convert alpha-ketoglutarate (α-KG, a normal TCA cycle intermediate) to D-2-hydroxyglutarate (D-2HG, an oncometabolite not produced in significant amounts by wild-type IDH) — IDH1/IDH2 mutations are gain-of-function because the mutant enzyme acquires a new catalytic activity (reduction of α-KG to D-2HG using NADPH) rather than losing its normal function; D-2HG accumulates to millimolar concentrations in IDH-mutant glioma cells creating a broad competitive inhibition of α-KG-dependent dioxygenases; TET2 (tet methylcytosine dioxygenase 2) is competitively inhibited by D-2HG — TET2 normally oxidizes 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as the first step in active DNA demethylation; TET2 inhibition by D-2HG prevents DNA demethylation creating genome-wide CpG hypermethylation — the G-CIMP (glioma CpG island methylator phenotype) that is the hallmark of IDH-mutant gliomas; KDM (histone lysine demethylase) family members including KDM4 (H3K9me2/3 demethylase), KDM6A (H3K27me3 demethylase), and KDM5 (H3K4me3 demethylase) are competitively inhibited by D-2HG — creating aberrant histone hypermethylation that represses differentiation gene programs maintaining oligodendroglial precursor cell stemness; curcumin inhibits IDH mutant-driven epigenetic programs through DNMT and HDAC inhibition in glioma cell models; quercetin inhibits EZH2 and HDAC in glioma cell models targeting the H3K27me3 hypermethylation from D-2HG/KDM inhibition.
The 1p/19q codeletion/CIC/FUBP1 pathway is the second defining molecular event and the genomic basis for the oligodendroglioma chemosensitivity: CIC (capicua) is a transcriptional repressor located at 19q13.2 — CIC normally represses ETS transcription factors (ETV1, ETV4, ETV5, ER81) by directly binding their promoters; CIC loss from 19q deletion (and additional CIC inactivating mutations in ~50-60% of oligodendrogliomas) creates constitutive de-repression of ETS transcription factors — constitutive ETS activity drives MAPK/ERK target gene expression (matrix metalloproteinases, RAS pathway components, cell migration genes) contributing to oligodendroglioma growth and invasion; FUBP1 (far upstream element-binding protein 1) is located at chromosome 1p31.1 — FUBP1 normally represses c-MYC transcription through direct binding of the far upstream element (FUSE) in the c-MYC promoter; FUBP1 loss from 1p deletion (and additional FUBP1 inactivating mutations in ~15-25%) creates constitutive c-MYC activation driving nucleotide biosynthesis, ribosome biogenesis, and polyamine synthesis; quercetin inhibits c-MYC expression in cancer cell models targeting the FUBP1-loss/c-MYC activation; quercetin also inhibits ETS-dependent MAPK/ERK signaling targeting the CIC-loss ETS de-repression.
The PI3K/AKT/mTOR pathway is activated in oligodendroglioma through multiple converging mechanisms: PIK3CA mutations in a subset; PTEN loss in a small subset; IGF-1R signaling from the oligodendroglioma microenvironment; IDH mutation-driven metabolic reprogramming indirectly activating mTORC1 through altered glutamine and α-KG availability; quercetin was confirmed to reduce p-AKT in U87-MG, U251, and SHG44 glioma cell lines by Western blot (PubMed25481090) — directly targeting PI3K/AKT pathway relevant to oligodendroglioma proliferative survival; EGCG inhibits PI3K/AKT and mTOR in glioma cell models; curcumin inhibits PI3K/AKT in glioma cell models.
Description
Oligodendroglioma (IDH-mutant and 1p/19q-codeleted) is one of three molecularly defined adult diffuse glioma entities recognized by the 2021 WHO Classification of Tumors of the Central Nervous System, comprising approximately 7 percent of all primary brain tumors. In the United States, approximately 2,500 to 4,000 new cases of oligodendroglioma are diagnosed annually. Globally, the annual incidence is estimated at approximately 0.5 to 1.0 new cases per 100,000 population. Oligodendroglioma has a bimodal age distribution with median age at diagnosis between 40 and 50 years, clearly distinguishing it from glioblastoma (median age ~64 years) and reflecting its earlier oncogenic initiation. Males are slightly more commonly affected than females.
The 2021 WHO classification assigns CNS WHO Grade 2 (lower-grade, no microvascular proliferation or necrosis, no CDKN2A/B homozygous deletion) or CNS WHO Grade 3 (anaplastic oligodendroglioma — increased mitoses, microvascular proliferation and/or necrosis, may have CDKN2A/B homozygous deletion) based on histological features and molecular markers. Approximately 70 to 75 percent of oligodendrogliomas are CNS WHO Grade 2 at diagnosis and approximately 20 to 25 percent are CNS WHO Grade 3.
Oligodendroglioma has a significantly more favorable prognosis than IDH-mutant astrocytoma and glioblastoma: median overall survival for CNS WHO Grade 2 oligodendroglioma is approximately 14 to 16 years in updated series; for CNS WHO Grade 3 approximately 7 to 10 years; the "triple positive" IDH+/1p19q+/TERTp+ constellation confers the most favorable prognosis among adult diffuse gliomas. Despite the relatively favorable prognosis, oligodendroglioma remains incurable with standard approaches as virtually all tumors recur and progress to higher grade over time.
The defining molecular event in oligodendroglioma is the IDH1 or IDH2 gain-of-function mutation creating the oncometabolite D-2-hydroxyglutarate (D-2HG): D-2HG competitively inhibits alpha-ketoglutarate (α-KG)-dependent dioxygenases including TET2 (DNA methylcytosine dioxygenase) and KDM histone demethylases, creating genome-wide CpG hypermethylation (G-CIMP) and altered histone methylation patterns that repress differentiation gene networks and maintain the stemness programs of oligodendroglial precursor cells.
Published laboratory research confirms quercetin from onions and kale inhibited cell viability dose-dependently in U87-MG, U251, and SHG44 human glioma cell lines; decreased migration confirmed; promoted apoptosis confirmed by Annexin V, beta-galactosidase, and DNA staining; p-AKT, p-ERK, Bcl-2, MMP-9, and fibronectin reduced confirmed by Western blot (PubMed25481090) — directly targeting PI3K/AKT and MAPK/ERK pathways relevant to oligodendroglioma proliferative signaling downstream of CIC loss and IDH-driven metabolic reprogramming.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with confirmed activity in human glioma cell lines relevant to oligodendroglioma biology. Quercetin from onions and kale was confirmed to inhibit cell viability dose-dependently in U87-MG, U251, and SHG44 human glioma cell lines; decreased migration confirmed by wound healing assay; promoted apoptosis confirmed by beta-galactosidase staining, DNA staining, and Annexin V-EGF/PI double staining; p-AKT, p-ERK, Bcl-2, MMP-9, and fibronectin protein levels significantly reduced confirmed by Western blot (PubMed25481090) — directly targeting PI3K/AKT and MAPK/ERK pathways relevant to oligodendroglioma; curcumin from turmeric inhibits HDAC and DNMT in glioma cell models targeting the IDH-driven G-CIMP epigenetic hypermethylation program; resveratrol inhibits SIRT1 and mTOR in glioma cell models; EGCG inhibits PI3K/AKT and EZH2 in glioma cell models; sulforaphane activates Nrf2 and inhibits HDAC in glioma cell models; apigenin inhibits PI3K/AKT and induces apoptosis in glioma cell models.
Plant Chemistry Detail
Quercetin from onions, kale, and apples has confirmed anti-glioma activity in a published study (PubMed25481090 — quercetin promotes cell apoptosis and inhibits MMP-9 and fibronectin via AKT and ERK signalling pathways in human glioma cells) using U87-MG human glioblastoma and U251 and SHG44 human glioma cell lines. In this confirmed study: quercetin inhibited cell viability in a dose-dependent manner in all three glioma cell lines confirmed by MTS assay at 48 and 72 hours; quercetin significantly decreased glioma cell migration confirmed by wound healing assay — directly relevant to oligodendroglioma diffuse infiltrative growth pattern along white matter tracts; quercetin promoted cell senescence confirmed by beta-galactosidase staining; quercetin promoted apoptosis confirmed by DNA staining and Annexin V-EGF/PI double staining; p-AKT (phosphorylated AKT, the PI3K/AKT activation marker) protein levels were significantly reduced confirmed by Western blot — directly targeting the PI3K/AKT pathway activated by PIK3CA mutations (subset of oligodendrogliomas) and by FUBP1-loss-driven c-MYC/mTORC1 activation; p-ERK (phosphorylated ERK, the MAPK/ERK activation marker) protein levels were significantly reduced confirmed by Western blot — directly targeting the MAPK/ERK pathway constitutively activated by CIC loss (~50-60% of oligodendrogliomas) de-repressing ETS transcription factors and their MAPK target genes; Bcl-2 (anti-apoptotic protein maintaining apoptosis resistance in glioma) protein levels significantly reduced confirmed by Western blot — targeting Bcl-2 upregulation driven by FUBP1-loss c-MYC activation in oligodendroglioma; MMP-9 and fibronectin protein levels significantly reduced confirmed by Western blot — targeting the invasive extracellular matrix program relevant to oligodendroglioma white matter infiltration.
Curcumin from turmeric inhibits HDAC3/6/8 in glioma cell models — directly targeting the histone hypermethylation landscape created by D-2HG-mediated KDM inhibition in IDH-mutant oligodendroglioma; curcumin also inhibits DNMT in glioma cell models targeting the G-CIMP/TET2-inhibited DNA hypermethylation from IDH-driven D-2HG accumulation; curcumin inhibits NF-kB in glioma cell models; curcumin inhibits PI3K/AKT and mTOR in glioma cell models. EGCG from green tea inhibits EZH2/PRC2-mediated H3K27me3 in glioma cell models — targeting the KDM6A/H3K27me3 hypermethylation from D-2HG; inhibits PI3K/AKT; and inhibits MAPK/ERK targeting the CIC-loss ETS/ERK cascade. Resveratrol inhibits SIRT1 and mTOR in glioma cell models and inhibits CIC-loss-driven MMP expression. Sulforaphane activates Nrf2/ARE and inhibits HDAC in glioma cell models providing antioxidant and epigenetic support. Apigenin inhibits PI3K/AKT and induces caspase-dependent apoptosis in glioma cell models.
Nutritional Focus
Nutritional focus in oligodendroglioma research is led by quercetin with confirmed anti-glioma activity: quercetin confirmed to inhibit cell viability dose-dependently in U87-MG, U251, and SHG44 human glioma cell lines; migration decreased confirmed by wound healing assay; apoptosis confirmed by Annexin V, beta-galactosidase, and DNA staining; p-AKT, p-ERK, Bcl-2, MMP-9, and fibronectin reduced confirmed by Western blot (PubMed25481090) — directly targeting PI3K/AKT (PIK3CA mutations in oligodendroglioma subset), MAPK/ERK (constitutively activated by CIC loss ~50-60% through ETS de-repression), Bcl-2 (upregulated by FUBP1-loss c-MYC in oligodendroglioma), and MMP-9/fibronectin (driving white matter infiltration in oligodendroglioma); curcumin from turmeric inhibiting HDAC and DNMT in glioma cell models — directly targeting the G-CIMP genome-wide CpG hypermethylation driven by IDH-mutation-mediated D-2HG accumulation and TET2 inhibition, the defining epigenetic hallmark of oligodendroglioma; EGCG from green tea inhibiting EZH2/PRC2 and PI3K/AKT in glioma cell models — targeting D-2HG/KDM6A-inhibited H3K27me3 accumulation; resveratrol inhibiting SIRT1 and mTOR in glioma cell models targeting FUBP1-loss-driven c-MYC/mTORC1 activation; sulforaphane activating Nrf2 and inhibiting HDAC targeting epigenetic dysregulation from IDH-driven D-2HG; apigenin inhibiting PI3K/AKT and inducing apoptosis in glioma models; and dietary fiber producing butyrate/SCFAs inhibiting HDAC targeting the extensive epigenetic reprogramming that defines IDH-mutant oligodendroglioma.
Research Notes
Oligodendroglioma epidemiology: ~2,500-4,000 new US cases/year; ~0.5-1.0 new cases/100,000 globally; ~7% of all primary brain tumors; median age at diagnosis 40-50 years; male slightly predominant; ~70-75% CNS WHO Grade 2 at diagnosis; ~20-25% CNS WHO Grade 3. 5-year OS grade 2 ~80-85%; 10-year ~70%; median OS ~14-16 years. Grade 3: 5-year OS ~60-70%; median OS ~7-10 years. 2021 WHO requires both IDH mutation AND 1p/19q codeletion for diagnosis. Molecular: IDH1 R132H ~90%; IDH2 R172 ~8%; 1p/19q codeletion t(1;19)(q10;p10) ~100%; TERT promoter C228T/C250T ~90% (triple positive constellation); CIC inactivating mutations ~50-60%; FUBP1 inactivating mutations ~15-25%; G-CIMP genome-wide CpG hypermethylation ~100%; MGMT promoter methylation ~90%; CDKN2A/B homozygous deletion small subset of grade 3 only; NOTCH1 mutations ~17%; PIK3CA subset; ATRX nuclear expression retained (distinguishing from astrocytoma). Radiological: frontal lobe ~50-55%; cortical ribbon growth pattern; gyriform calcifications ~80% on CT; T2/FLAIR hyperintense mass; often non-enhancing grade 2. D-2HG oncometabolite from IDH mutation inhibits TET2 (DNA demethylation) and KDM histone demethylases creating G-CIMP and histone hypermethylation. CIC loss creates constitutive ETS/MAPK activation. FUBP1 loss creates constitutive c-MYC. Quercetin U87-MG/U251/SHG44 glioma (PubMed25481090): viability inhibited dose-dependent MTS; migration decreased wound healing; apoptosis confirmed Annexin V/beta-gal/DNA staining; p-AKT/p-ERK/Bcl-2/MMP-9/fibronectin reduced Western blot confirmed.
Notes Visibility
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Lions Mane,Cremini,Portobello,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Celery, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,calcium,potassium,iron,quercetin,curcumin,egcg,resveratrol,sulforaphane,beta-carotene,anthocyanins,dietary-fiber,l-theanine
